Applied BioMath, LLC Announces Partnership with Antengene for Systems Pharmacology Modeling in Oncology
Applied BioMath | December 09, 2020
Applied BioMath, the business chief in applying frameworks pharmacology and unthinking demonstrating, reproduction, and examination to de-hazard drug innovative work, today reported a joint effort with Antengene Corporation for the advancement of a frameworks pharmacology displaying in immuno-oncology. Applied BioMath will build up a frameworks pharmacology model for a PDL1/41BB bispecific immunizer, ATG-101, in immuno-oncology signs. The model will be utilized to anticipate clinical beginning and useful portions for first-in-quite a while. "Antengene Corporation is devoted to growing first-in-class as well as top tier treatments in oncology," said Dirk Hoenemann, M.D., VP, Head of Medical Affairs for Asia Pacific Region (APAC) and Early Clinical Development. "We chose to work together with Applied BioMath with an end goal to give ourselves the most noteworthy probability conceivable of anticipating exact beginning and effectual dosages which is a basic piece of our first-in-quite a while."
Applied BioMath utilizes a thorough fit-for-reason model advancement measure which quantitatively coordinates information about therapeutics with a comprehension of its component of activity with regards to human sickness systems. Their methodology utilizes exclusive calculations and programming that were planned explicitly for frameworks pharmacology model turn of events, reenactment, and examination. "Foreseeing beginning and effectual portions for first-in-quite a while is non-paltry for complex therapeutics, for example, Antengene's bispecific restorative," said Dr. John Burke, Ph.D., Co-Founder, President, and CEO of Applied BioMath. "We have created calculations and devices explicitly for this reason that have a demonstrated history of foreseeing such portions. We anticipate working together with Antengene to help them in this venture."
About Applied BioMath
Founded in 2013, Applied BioMath's mission is to revolutionize drug invention. Applied BioMath uses mathematical modeling and simulation to provide quantitative and predictive guidance to biotechnology and pharmaceutical companies to help accelerate and de-risk drug research and development. Their approach employs proprietary algorithms and software to support groups worldwide in decision-making from early research through clinical trials. The Applied BioMath team leverages their decades of expertise in biology, mathematical modeling and analysis, high-performance computing, and industry experience to help groups better understand their candidate, its best-in-class parameters, competitive advantages, patients, and the best path forward into and in the clinic. For more information about Applied BioMath and its services, visit www.appliedbiomath.com.
Antengene Corporation Limited ("Antengene", SEHK: 6996.HK) is a biopharmaceutical company with an integrated drug discovery and clinical development approach, anchored in Asia Pacific with a global footprint. Antengene aims to provide the most advanced anti-cancer drugs to patients in China, the Asia Pacific Region and around the world. Since official operation in April 2017, Antengene has built a pipeline of 12 clinical and pre-clinical stage assets, obtained 10 IND approvals and has 9 ongoing cross-regional clinical trials in Asia Pacific. At Antengene, we focus on developing drug candidates with novel MoAs and first-in-class/best-in-class potential to address significant unmet medical needs. The vision of Antengene is to "Treat Patients Beyond Borders" through discovery, development and commercialization of first-in-class/best-in-class therapeutics.